Relation of diabetes to mild cognitive impairment

Archives of Neurology

Volumn 64, Issue 4, 2007, Pages 570-575

  Luchsinger, José A ^a,b,c,d   Reitz, Christiane ^c   Patel, Bindu ^b   Tang, Ming Xin ^b   Manly, Jennifer J ^b,c,d   Mayeux, Richard ^b,c,d  

^a Och Spine at New York Presbyterian Hospitals   (United States)

^b Joseph P Mailman School of Public Health ^*  (United States)

^c Taub Institute for Research on Alzheimer's Disease and the Aging Brain and the Gertrude H Sergievsky Center   (United States)

^d NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN E;

AGED; ALLELE; ALZHEIMER DISEASE; ARTICLE; COGNITION; COGNITIVE DEFECT; CONTROLLED STUDY; DEMENTIA; DEMOGRAPHY; DIABETES MELLITUS; FEMALE; FOLLOW UP; HEART DISEASE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; NEUROPSYCHOLOGICAL TEST; PREVALENCE; PRIORITY JOURNAL; RISK FACTOR; SELF REPORT; SMOKING HABIT; STROKE;

EID: 34247110809     PISSN: 00039942     EISSN: 15383687     Source Type: Journal    
DOI: 10.1001/archneur.64.4.570     Document Type: Article

References (54)

1. Peila R, Rodriguez BL, Launer LJ. Type 2 diabetes, APOE gene, and the risk for dementia and related pathologies: the Honolulu-Asia Aging Study. Diabetes. 2002;51:1256-1262.
2. Luchsinger JA, Tang MX, Stern Y, Shea S, Mayeux R. Diabetes mellitus and risk of Alzheimer's disease and dementia with stroke in a multiethnic cohort. Am J Epidemiol. 2001;154:635-641.
3. Ott A, Stolk RP, van Harskamp F, Pols HA, Hofman A, Breteler MM. Diabetes mellitus and the risk of dementia: the Rotterdam Study. Neurology. 1999;53:1937-1942.
4. Ott A, Stolk RP, Hofman A, van Harskamp F, Grobbee DE, Breteler MM. Association of diabetes mellitus and dementia: the Rotterdam Study. Diabetologia. 1996;39:1392-1397.
5. Leibson CL, Rocca WA, Hanson VA, et al. Risk of dementia among persons with diabetes mellitus: a population- based cohort study. Am J Epidemiol. 1997;145:301-308.
6. Luchsinger JA, Tang MX, Shea S, Mayeux R. Hyperinsulinemia and risk of Alzheimer disease. Neurology. 2004;63:1187-1192.
7. Farris W, Mansourian S, Chang Y, et al. Insulin-degrading enzyme regulates the levels of insulin, amyloid beta-protein, and the beta-amyloid precursor protein intracellular domain in vivo. Proc Natl Acad Sci U S A. 2003;100:4162-4167.
8. Qiu WQ, Walsh DM, Ye Z, et al. Insulin-degrading enzyme regulates extracellular levels of amyloid beta- protein by degradation. J Biol Chem. 1998;273:32730-32738.
9. Selkoe DJ. The origins of Alzheimer disease: a is for amyloid. JAMA. 2000;283:1615-1617.
10. Smith MA, Sayre LM, Perry G. Diabetes mellitus and Alzheimer's disease: glycation as a biochemical link. Diabetologia. 1996;39:247.
11. Harris MI. Diabetes in America: epidemiology and scope of the problem. Diabetes Care. 1998;21(suppl 3):C11-C14.
12. Luchsinger JA Diabetes. In: Aguirre-Molina M, Molina CW, Zambrana RE, eds. Health Issues in the Latino Community. San Francisco, Calif: Jossey-Bass; 2001:277-300.
13. Luchsinger JA, Reitz C, Honig LS, Tang MX, Shea S, Mayeux R. Aggregation of vascular risk factors and risk of incident Alzheimer disease. Neurology. 2005;65:545-551.
14. Petersen RC. Normal aging, mild cognitive impairment, and early Alzheimer's disease. Neurologia. 1995;1:326-344.
15. Petersen RC. Mild cognitive impairment as a diagnostic entity. J Intern Med. 2004;256:183-194.
16. Petersen RC, Doody R, Kurz A, et al. Current concepts in mild cognitive impairment. Arch Neurol. 2001;58:1985-1992.
17. Luchsinger JA, Mayeux R. Cardiovascular risk factors and Alzheimer's disease. Curr Atheroscler Rep. 2004;6:261-266.
18. Tang MX, Stern Y, Marder K, et al. The APOE-epsilon4 allele and the risk of Alzheimer disease among African Americans, whites, and Hispanics. JAMA. 1998;279:751-755.
19. Stern Y, Andrews H, Pittman J, et al. Diagnosis of dementia in a heterogeneous population: development of a neuropsychological paradigm-based diagnosis of dementia and quantified correction for the effects of education. Arch Neurol. 1992;49:453-460.
20. Buschke H, Fuld PA. Evaluating storage, retention, and retrieval in disordered memory and learning. Neurology. 1974;24:1019-1025.
21. Benton AL. The Benton Visual Retention Test. New York, NY: Psychological Corp; 1955.
22. Folstein MF, Folstein SE, McHugh PR. "Mini-Mental State": a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12:189-198.
23. Weschler D. Wechsler Memory Scale-Revised Manual. New York, NY: Psychological Corp; 1987.
24. Mattis S. Mental Status Examination for Organic Mental Syndrome in the Elderly Patient. New York, NY: Grune & Stratton; 1976.
25. Kaplan E, Goodglass H, Weintraub S. Boston Naming Test. Philadelphia, Pa: Lea & Febiger; 1983.
26. Benton AL, Hamsher KD. Multilingual Aphasia Examination. Iowa City: University of Iowa; 1976.
27. Goodglass H, Kaplan E. Assessment of Aphasia and Related Disorders. Philadelphia, Pa: Lea & Febiger; 1983.
28. Goodglass H, Kaplan E. The Assessment of Aphasia and Related Disorders. Philadelphia, Pa: Lea & Febiger; 1972.
29. Rosen W. The Rosen Drawing Test. Bronx, NY: Veterans Administration Medical Center; 1981.
30. Manly JJ, Bell-McGinty S, Tang M-X, Schupf N, Stern Y, Mayeux R. Implementing diagnostic criteria and estimating frequency of mild cognitive impairment in an urban community. Arch Neurol. 2005;62:1739-1746.
31. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington, DC: American Psychiatric Association; 1994.
32. Hughes CP, Berg L, Danziger WL, Coben LA, Martin RL. A new clinical scale for the staging of dementia. Br J Psychiatry. 1982;140:566-572.
33. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984;34:939-944.
34. Petersen RC, Stevens JC, Ganguli M, Tangalos EG, Cummings JL, DeKosky ST. Early detection of dementia: mild cognitive impairment (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2001;56:1133-1142.
35. Lopes-Virella MF, Stone P, Ellis S, Colwell JA. Cholesterol determination in high-density lipoproteins separated by three different methods. Clin Chem. 1977;23:882-884.
36. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18:499-502.
37. Hixson JE, Vernier DT. Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI. J Lipid Res. 1990;31:545-548.
38. Mayeux R, Ottman R, Maestre G, et al. Synergistic effects of traumatic head injury and apolipoprotein-epsilon 4 in patients with Alzheimer's disease. Neurology. 1995;45:555-557.
39. Fleiss JL. Statistical Methods for Rates and Proportions. 2nd ed. New York: Joseph Wiley & Sons; 1981.
40. Cox DR, Oakes D. Analysis of Survival Data. London, England: Chapman & Hall; 1984.
41. Kahn HA, Sempos CT. Statistical Methods in Epidemiology. Oxford, England: Oxford University press; 1989.
42. Luis CA, Loewenstein DA, Acevedo A, Barker WW, Duara R. Mild cognitive impairment: directions for future research. Neurology. 2003;61:438-444.
43. Curb JD, Rodriguez BL, Abbott RD, et al. Longitudinal association of vascular and Alzheimer's dementias, diabetes, and glucose tolerance. Neurology. 1999;52:971-975.
44. Tatemichi TK, Desmond DW, Paik M, et al. Clinical determinants of dementia related to stroke. Ann Neurol. 1993;33:568-575.
45. Vermeer SE, Prins ND, den Heijer T, Hofman A, Koudstaal PJ, Breteler MM. Silent brain infarcts and the risk of dementia and cognitive decline. N Engl J Med. 2003;348:1215-1222.
46. Honig LS, Kukull W, Mayeux R. Atherosclerosis and AD: analysis of data from the US National Alzheimer's Coordinating Center. Neurology. 2005;64:494-500.
47. Honig LS, Tang MX, Albert S, et al. Stroke and the risk of Alzheimer disease. Arch Neurol. 2003;60:1707-1712.
48. Reaven GM, Laws A. Insulin Resistance: The Metabolic Syndrome X. Totowa, NJ: Humana Press; 1999.
49. Sasaki N, Fukatsu R, Tsuzuki K, et al. Advanced glycation end products in Alzheimer's disease and other neurodegenerative diseases. Am J Pathol. 1998;153:1149-1155.
50. Markesbery WR. Oxidative stress hypothesis in Alzheimer's disease. Free Radic Biol Med. 1997;23:134-147.
51. Tang MX, Cross P, Andrews H, et al. Incidence of AD in African-Americans, Caribbean Hispanics, and Caucasians in northern Manhattan. Neurology. 2001;56:49-56.
52. Scarmeas N, Stern Y. Cognitive reserve and lifestyle. J Clin Exp Neuropsychol. 2003;25:625-633.
53. Harris MI, Flegal KM, Cowie CC, et al. Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in U.S. adults: The Third National Health and Nutrition Examination Survey, 1988-1994. Diabetes Care. 1998;21:518-524.
54. Centers for Disease Control and Prevention. Trends in the prevalence and incidence of self-reported diabetes mellitus-United States, 1980-1994.MMWR Morb Mortal Wkly Rep. 1997;46:1014-1018.